Terri Lynn Parker MD

Assistant Professor of Medicine (Hematology); Assistant Professor

Specialties & Subspecialties

Cancer Center, Yale: Hematology Program


Education & Training

  • B.S., University of Pittsburgh (2001)
  • M.D., St. George's University School of Medicine Grenada (2005)
  • Residency, University of Connecticut Health Center , Internal Medicine (2005 - 2008)
  • Fellowship, University of Connecticut Health Center , Hospice and Palliative Med (2008 - 2009)
  • Fellowship, Yale University School of Medicine , Hematology and Medical Oncology (2009 - 2012)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | NA

Clinical Interests

Benign and Malignant Hematology; Hospice and Palliative Medicine

Cancers Treated


Board Certifications

  • Hematology, Internal Medicine, Board Certified (2012)
  • Internal Medicine, Board Certified (2008)
  • Hospice & Palliative Medicine, Board Certified (2010)

Clinical Trials

ConditionsStudy Title
Leukemia, not otherwise specified and Myeloid and Monocytic LeukemiaA Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Ill-Defined Sites and Unknown SitesA Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises
Leukemia, not otherwise specified and Myeloid and Monocytic LeukemiaAn Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia

Edit Profile